Denosumab for Treatment of Hypercalcemia of Malignancy in Patients with Solid Tumors or Hematological Malignancies Refractory to IV Bisphosphonates: A Single-Arm Multicenter Study
Mimi I. Hu(The University of Texas MD Anderson Cancer Center), Howard Yeh(Hospital de Santa Maria), Ilya Glezerman(Memorial Sloan Kettering Cancer Center), Wendy Ying(Allogene Therapeutics (United States)), Rasim Gucalp(Montefiore Medical Center), Sophie Leboulleux(Geneva College), Bennett W. Yu(Moffitt Cancer Center), Karl Insogna(Yale University), Waldemar Misiorowski(Postgraduate School of Molecular Medicine)
Cited by 4
Related Papers
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
|Journal of Clinical Oncology|2011|1.3k
Combination Chemotherapy in Advanced Adrenocortical Carcinoma
|New England Journal of Medicine|2012|863
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers
|New England Journal of Medicine|2020|766
Prognostic Factors for Persistent or Recurrent Disease of Papillary Thyroid Carcinoma with Neck Lymph Node Metastases and/or Tumor Extension beyond the Thyroid Capsule at Initial Diagnosis
|The Journal of Clinical Endocrinology & Metabolism|2005|589
Precision Targeted Therapy with BLU-667 for <i>RET</i>-Driven Cancers
|Cancer Discovery|2018|392